Setting the Stage for Engineered B-Cell Therapies in Cancer and Autoimmune Disease
November 7th 2023David Rawlings, MD, the director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute, discussed findings from several preclinical studies that could help push engineered B-cell therapies towards clinical trials.
University of Manchester Launches MPS II Gene Therapy Trial, Picking Up Where AVROBIO Left Off
November 5th 2023UoM was previously collaborating on the development of AVR-RD-05 with AVROBIO, but regained the license to the HSC gene therapy following the company’s cessation of development on all programs.
FDA Staff Call for Further Study Considerations for Exa-Cel Ahead of Decision in Sickle Cell
October 29th 2023The therapy’s PDUFA date is scheduled for December 8, 2023, and an Advisory Committee is set to meet on October 31, 2023, to discuss the treatment’s potential approval for sickle cell disease.
Brett Kopelan, MA, on the Future Treatment of Epidermolysis Bullosa With Advanced Therapeutics
October 29th 2023In observance of Epidermolysis Bullosa Awareness Week, the executive director of debra of America discussed how a combination of advanced and topical approaches may represent the future of EB treatment.